Clinical Trials
9 trialsNCT02567435 2026-05-27
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04994132 2026-05-05
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT05304585 2026-05-05
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Recruiting
NCT03296371 2026-02-06
Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
Children's Oncology Group
Active not recruiting
NCT03382158 2025-01-30
International PPB/DICER1 Registry
Children's Hospitals and Clinics of Minnesota
Recruiting
NCT06669013 2024-11-01
FollowTheDIN
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Recruiting
NCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00923351 2018-06-15
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed